CD276 and posterior cortical atrophy: Phase I study of anti-B7-H3 bispecific antibody in PCa patients enhanced T cells activation and proliferation as well as production of cytokines and mediators (granzyme/perforin) that eliminates tumour cells, qualifying B7-H3 a potential target for PCa immunotherapy [145].